-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
GLP-1 RA is not insulin, but a new type of insulin secretagogue.
GLP-1 RA is not insulin, but a new type of insulin secretagogue.
Trulicity ( dulaglutide ) is a glucagon-like peptide -1 ( GLP-1 ) receptor agonist ( RA ), injected once a week, combined with diet control and exercise, for 2 type diabetes ( diabetes mellitus T2DM ) to improve glycemic control in adult patients
2020 Nian 09 Yue 03 RiLilly ( Eli Lilly ) announced that the US Food and Drug Administration Bureau ( the FDA ) has approved the pull of the glycopeptide 2 additional doses ( 3.
2020 Nian 09 Yue 03 Ri Lilly ( Eli Lilly ) announced that the US Food and Drug Administration Authority ( managing the FDA the FDA ) has approved the pull of the glycopeptide 2 additional doses ( 3.
Currently, dulaglycotide is being developed for non-alcoholic steatohepatitis ( NAH ) and chronic kidney disease
In this 2b of the study, 834 name BMI≥25 kg / m2 and metformin inadequate control T2DM adults ( HbAIc of 7.
In this 2b of the study, 834 name BMI≥25 kg / m2 and metformin inadequate control of metformin T2DM adults ( HbAIc of 7.
Dulaglutide (double-blind) and liraglutide (open-label) are given by subcutaneous injection once a day
Dulaglutide (double-blind) and liraglutide (open-label) are given by subcutaneous injection once a day
The results showed that, compared with placebo, the degree of pull glycopeptide compared with placebo, the degree of pull glycopeptide compared with placebo, the degree of pull glycopeptide At 14 weeks and 54 weeks significantly reduced HbA1c and Body weight (all P<0.
Changes in blood glucose and weight results from baseline to week 54 between different groups
Changes in blood glucose and weight results from baseline to week 54 between different groupsDulaglutide treatment for 54 weeks improved blood sugar control and weight loss in overweight/obese and type 2 diabetes patients
Dulaglutide treatment for 54 weeks improved blood sugar control and weight loss in overweight/obese and type 2 diabetes patients
references:
references:Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study .
Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study .
Diabetes Care 2021 Jun; 44(6): 1433-1442.
https://doi.
org/ 10.
2337 / dc20-2151 Effects of Metabolic Cotadutide oN and the Parameters in Hepatic or Obesity and Overweight Adults With the Type 2 Diabetes: A-54 is Week Randomized Phase 2B Study
in this message
